Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: a systematic review.

The authors hunted for gold-standard drug trials. They wanted randomized controlled trials (RCTs) on antipsychotics for adults who have both intellectual disability (ID) and schizophrenia.

They searched every major medical database up to 1998. Two reviewers checked each possible paper. In the end, they found zero RCTs that met their rules.

No RCTs exist. None. Doctors are prescribing without clear evidence.

The review only located case reports and small chart reviews. These weaker studies cannot tell us if the drugs truly help or harm this group.

Aznar et al. (2005) later published a single case where clozapine helped one man with ID and psychosis, but it also caused seizures. That case is part of the tiny evidence pool Matson et al. (1999) warned about.

Iivanainen (1998) reviewed lamotrigine for seizures in ID and reached a firm “start low, go slow” rule. That review shows high-quality drug advice is possible when RCT data exist.

Reiss et al. (1993) argued that psychiatric labels often fail people with ID. Their paper predicted the evidence gap Matson et al. (1999) later proved. Together, the two articles show the field has talked about the problem for decades yet still lacks trials.

If you serve adults with dual diagnosis, you now know the drug list is built on sand. Share this fact with prescribers and families. Push for careful single-subject data: track target symptoms, side effects, and adaptive skills each visit. Your notes could become part of the evidence base we still need.